Åslaug Helland

Professor, group leader
Division of Cancer Medicine, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway

Disclosure information not submitted.

Presentation(s):

• Hypothetical target trial to compare the effectiveness of atezolizumab, pembrolizumab and nivolumab in second line treatment of advanced non-small cell lung cancer

  Tuesday, August 27, 2024
  2:15 PM – 2:30 PM CEST